What is MNPR's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.53B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for MNPR?

P/E (TTM) is n/a and 52-week range is $50.07 to $124.82 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s MNPR figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for MNPR?

The company profile lists net income (TTM) near $-15M, EPS (TTM) near $-2.17 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Monopar Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Wilmette, Illinois, US, 6.7M shares outstanding, ISIN US61023L2079 when available from company profile and filing metadata.

Monopar Therapeutics Inc

$MNPR

Health Care · Biotechnology

IR Run Scenarios

$78.96

-5.98%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. The company is headquartered in Wilmette, Illinois and currently employs 22 full-time employees. The company went IPO on 2019-12-19. The firm developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.

Employees

Website

www.monopartx.com/

IPO

2019-12-19

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)